Page 2 - Rose Weldon News Today

Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed...

Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer patients open to enrollment Initial monotherapy clinical data for CLN-619 presented at... -Today at 07:02 am- MarketScreener

/PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc., announced today the launch of the REZILIENT3 trial...

CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial...

CAMBRIDGE, Mass., Oct. 03, 2022 -- Cullinan Oncology, Inc.  today announced that the compensation committee of the Companys Board of Directors granted stock option awards to purchase an... | October 3, 2022

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee...

CAMBRIDGE, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee...

With the CDC suggesting that adenovirus should be considered in diagnosis of acute hepatitis in children, amidst a possible outbreak of cases in Europe and the U.S., some pediatricians are wondering what to look out for in their own practices.

DENVER — The first randomized controlled trial of furosemide for preterm infants at high risk for bronchopulmonary dysplasia found an increased risk for electrolyte adverse events but no greater risk for overall safety events.

DENVER — A randomized controlled trial found that early targeted treatment with ibuprofen did not reduce mortality among 72-hour-old extremely preterm infants with a large patent ductus arteriosus, researchers reported here.